AMGEN Inc
NASDAQ: AMGN
$321.79
+$2.50 (+0.8%)
Closing Price on November 6, 2024
AMGN Articles
The top analyst upgrades, downgrades and other research calls from Monday include Amgen, Boeing, Chevron, Exxon Mobil, Foot Locker, Lowe's, Nokia, PayPal, Sprint and Wells Fargo.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include Alibaba, Alphabet, Amazon, Amgen, Apple, Mastercard, Nokia, Shopify and US Steel.
Published:
Last Updated:
The January 12 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Amgen, Caterpillar, Dollar General, Duke Energy, General Electric, Honeywell, 3M, Netflix and Sprint.
Published:
Last Updated:
Apple indicated that it will pay $38 billion in repatriation taxes under the new tax law. Apple says that it is already the largest U.S. taxpayer and that a payment of that size likely would be the...
Published:
Last Updated:
The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Published:
Last Updated:
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
Published:
Last Updated:
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
Published:
Last Updated:
The December 15 short interest data have been compared with the previous report, and short interest in the selected biotech stocks increased.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
Published:
Last Updated:
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Published:
Last Updated:
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Published:
Last Updated:
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Abercrombie & Fitch, Amgen, Electronic Arts, General Motors, Goldcorp, Shopify, 3D Systems and Under Armour.
Published:
Last Updated: